Fortress Biotech, Inc.
Data quality: 100%
$2.35
▼
$0.08
(-3.29%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-2.07%
Growth
Revenue Growth (5Y)
-2.07%
Below sector avg (1.72%)
Revenue (1Y)9.69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
13.66%
Above sector avg (-54.68%)
ROIC-48.30%
Net Margin10.77%
Op. Margin-111.00%
Safety
Debt / Equity
0.86
Above sector avg (0.30)
Current Ratio2.19
Interest Coverage-6.95
Valuation
PE (TTM|NTM|2027)
11.27 | 4.81 | 4.73
Above sector avg (-1.49)
P/B Ratio1.37
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -2.07% annually over 5 years
ROE of 13.66% — decent returns on equity
Negative free cash flow of -65.78 M
P/E of 11.27 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11.76%
Price History
Financial Trends
Analyst Price Target
2 analysts
Buy
+357.4%
upside to target
Current
$2.35
Consensus Target
$10.75
$4.50
Low
$17.00
High
Forecast
Forward P/E
4.81
Forward EPS
$0.51
Est. Revenue
135.31 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.22
·
Rev Est: 16.34 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.48 | -$0.51 | $0.11 | -$0.21 | — | — |
| Estimate | -$0.44 | -$0.31 | -$0.63 | $0.11 | -$0.22 | -$0.19 |
| Surprise | -9.09% | -65.29% | +117.60% | -290.91% | — | — |
Growth
Rev 5Y: -2.07% · Earnings 1Y: N/A
Growth
Rev 5Y: -2.07% · Earnings 1Y: N/A| Revenue Growth (1Y) | 9.69% | Revenue Growth (3Y) | -13.48% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -2.07% | Earnings Growth (5Y) | N/A |
Profitability
ROE: 13.66% · Net Margin: 10.77%
Profitability
ROE: 13.66% · Net Margin: 10.77%| Revenue (TTM) | 63.26 M | Net Income (TTM) | 6.82 M |
| ROE | 13.66% | ROA | 3.99% |
| Gross Margin | N/A | Operating Margin | -111.00% |
| Net Margin | 10.77% | Free Cash Flow (TTM) | -65.78 M |
| ROIC | -48.30% | FCF Growth (3Y) | N/A |
Safety
D/E: 0.86 · Current: 2.19
Safety
D/E: 0.86 · Current: 2.19| Debt / Equity | 0.86 | Current Ratio | 2.19 |
| Interest Coverage | -6.95 | Asset Turnover | 0.37 |
| Working Capital | 64.44 M | Tangible Book Value | 27.19 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: 11.27 · EV/EBITDA: N/A
Valuation
P/E: 11.27 · EV/EBITDA: N/A| P/E Ratio | 11.27 | Forward P/E | 4.81 |
| P/B Ratio | 1.37 | P/S Ratio | 1.21 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0.57 | Fwd Earnings Yield | 20.79% |
| FCF Yield | -85.64% | ||
| Market Cap | 76.80 M | Enterprise Value | 38.36 M |
Per Share
EPS: -0.07 · FCF/Share: -2.04
Per Share
EPS: -0.07 · FCF/Share: -2.04| EPS (Diluted TTM) | -0.07 | Revenue / Share | 1.96 |
| FCF / Share | -2.04 | OCF / Share | -2.04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: -965.18% · CapEx/Rev: N/A
Efficiency
FCF Conv: -965.18% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | -965.18% |
| SBC-Adj. FCF | -98.63 M | Growth Momentum | 11.76 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 63.26 M | 57.68 M | 84.51 M | 75.74 M | 68.79 M |
| Net Income | 6.82 M | -46.00 M | -60.64 M | -86.58 M | -64.70 M |
| EPS (Diluted) | -0.07 | -2.69 | -8.47 | -0.97 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -70.22 M | -110.38 M | -142.34 M | -203.56 M | -188.54 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | 106.07 M | 134.88 M | 128.87 M |
| SG&A Expenses | 96.40 M | 87.73 M | 94.12 M | 113.66 M | 86.84 M |
| D&A | — | — | — | — | — |
| Interest Expense | 10.11 M | 13.53 M | 15.32 M | 12.48 M | 15.31 M |
| Income Tax | -620,000.0 | 312,000.0 | 521,000.0 | 449,000.0 | 473,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 185.55 M | 144.22 M | 167.53 M | 294.30 M | 396.50 M |
| Total Liabilities | 123.37 M | 145.87 M | 165.94 M | 244.28 M | 170.63 M |
| Shareholders' Equity | 49.87 M | 22.74 M | 22.54 M | 41.72 M | 108.67 M |
| Total Debt | 52.42 M | 57.96 M | 60.86 M | 91.73 M | 42.94 M |
| Cash & Equivalents | 79.38 M | 57.26 M | 80.93 M | 178.27 M | 305.74 M |
| Current Assets | 123.84 M | 90.37 M | 117.02 M | 230.43 M | 346.46 M |
| Current Liabilities | 49.74 M | 71.40 M | 84.91 M | 127.72 M | 101.04 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 11.3 | -1.5 |
| P/B | 1.4 | 1.6 |
| ROE % | 13.7 | -54.7 |
| Net Margin % | 10.8 | -41.5 |
| Rev Growth 5Y % | -2.1 | 1.7 |
| D/E | 0.9 | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"FBIO","listing_kind":"stock","pathname":"/stocks/fbio","exchange":"NASDAQ","country":"US"}}